永顺生物
(839729)
| 流通市值：7.30亿 | | | 总市值：25.97亿 |
| 流通股本：7682.50万 | | | 总股本：2.73亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 65,456,650.96 | 268,985,086.87 | 200,361,538.4 | 119,176,173.44 |
| 营业收入 | 65,456,650.96 | 268,985,086.87 | 200,361,538.4 | 119,176,173.44 |
| 二、营业总成本 | 58,827,999.72 | 233,726,259.2 | 171,882,299.31 | 101,264,705.6 |
| 营业成本 | 28,635,885.69 | 112,624,020.37 | 85,158,653.22 | 49,233,656.06 |
| 税金及附加 | 491,950.66 | 2,055,128.1 | 1,531,980.55 | 959,441.66 |
| 销售费用 | 15,134,318.05 | 57,142,641.58 | 43,690,401.29 | 26,632,345.33 |
| 管理费用 | 9,519,687.11 | 40,345,633.05 | 27,037,535.93 | 16,197,733.88 |
| 研发费用 | 5,153,474.56 | 22,958,367.13 | 15,616,737.4 | 9,793,094.43 |
| 财务费用 | -107,316.35 | -1,399,531.03 | -1,153,009.08 | -1,551,565.76 |
| 其中:利息费用 | 1,660.09 | 757,024.51 | 622,688.72 | 376,822.73 |
| 其中:利息收入 | 15,228.51 | 2,132,663.71 | 2,064,731.92 | 1,860,619.51 |
| 加:公允价值变动收益 | 124,881.69 | 334,929.02 | 283,903.39 | 324,266.06 |
| 加:投资收益 | 2,515,481.37 | 8,664,786.36 | 5,972,917.31 | 3,411,320.09 |
| 资产处置收益 | - | - | 206,213.59 | 206,213.59 |
| 资产减值损失(新) | -945,420.1 | -3,191,563.71 | -5,837,805.15 | -5,697,619.19 |
| 信用减值损失(新) | -464,449.33 | -384,066.67 | 556,040.58 | -818,910 |
| 其他收益 | 859,285.25 | 3,501,131.4 | 2,756,135.7 | 1,945,116.63 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 8,718,430.12 | 44,184,044.07 | 32,416,644.51 | 17,281,855.02 |
| 加:营业外收入 | 8,335.5 | 364,782.69 | 152,531.44 | 132,237.44 |
| 减:营业外支出 | 15,711.56 | 40,863.04 | 40,275.36 | 39,975.42 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 8,711,054.06 | 44,507,963.72 | 32,528,900.59 | 17,374,117.04 |
| 减:所得税费用 | 795,023.24 | 4,364,541.28 | 3,565,430.4 | 1,840,218.63 |
| 六、净利润 | 7,916,030.82 | 40,143,422.44 | 28,963,470.19 | 15,533,898.41 |
| 持续经营净利润 | 7,916,030.82 | 40,143,422.44 | 28,963,470.19 | 15,533,898.41 |
| 归属于母公司股东的净利润 | 7,916,030.82 | 40,143,422.44 | 28,963,470.19 | 15,533,898.41 |
| (一)基本每股收益 | 0.03 | 0.15 | 0.11 | 0.06 |
| (二)稀释每股收益 | 0.03 | 0.15 | 0.11 | 0.06 |
| 九、综合收益总额 | 7,916,030.82 | 40,143,422.44 | 28,963,470.19 | 15,533,898.41 |
| 归属于母公司股东的综合收益总额 | 7,916,030.82 | 40,143,422.44 | 28,963,470.19 | 15,533,898.41 |
| 公告日期 | 2025-04-28 | 2025-04-28 | 2024-10-25 | 2024-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |